Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kirson

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Neuro-Aids|January 1, 1996
Neurological Symptoms, Not Signs,<br />Are Common in Early HIV InfectionP Mehta, S J Gulevich, L J Thal, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2007
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumorsEilon D Kirson, Vladimír Dbalý, Frantisek Tovarys, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2020
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyTali Voloshin, Noa Kaynan, Shiri Davidi, et al.
International Journal of Cancer|August 26, 2016
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoTali Voloshin, Mijal Munster, Roni Blatt, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Neuro-Aids|January 1, 1996
Neurological Symptoms, Not Signs,<br />Are Common in Early HIV InfectionP Mehta, S J Gulevich, L J Thal, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2007
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumorsEilon D Kirson, Vladimír Dbalý, Frantisek Tovarys, et al.
Cancer Immunology, Immunotherapy : CII|March 8, 2020
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapyTali Voloshin, Noa Kaynan, Shiri Davidi, et al.
International Journal of Cancer|August 26, 2016
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoTali Voloshin, Mijal Munster, Roni Blatt, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
JAMA|December 21, 2017
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew Kanner, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
Pageof 4